Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Prevention of Postoperative Atrial Fibrillation

This study has been completed.
Information provided by (Responsible Party):
George Washington University Identifier:
First received: November 14, 2012
Last updated: December 3, 2012
Last verified: December 2012
The primary aim of this study is to determine the safest and most effective therapeutic strategy to decrease the incidence of postoperative atrial fibrillation following cardiac surgery in an era with shorter ICU and hospital length of stay. A secondary goal is to evaluate the length of hospital stay associated with each treatment strategy.

Postoperative Atrial Fibrillation

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A New Therapeutic Strategy to Reduce the Incidence of Postoperative Atrial Fibrillation

Resource links provided by NLM:

Further study details as provided by George Washington University:

Primary Outcome Measures:
  • occurrence of atrial fibrillation [ Time Frame: postoperative day 0-day of discharge (an average of 5 days) ]
    The primary endpoint of this study was also the occurrence of atrial fibrillation for any length of time requiring treatment as a result of symptoms or hemodynamic compromise.

  • occurrence of atrial fibrillation [ Time Frame: postoperative day 0-day of discharge (an average of 5 days) ]
    The primary endpoint of this study was the occurrence of atrial fibrillation lasting longer than five minutes

Secondary Outcome Measures:
  • length of stay [ Time Frame: participants will be followed for the duration of hospital stay, an expected average of 5 days ]
    The secondary endpoint was the length of hospital stay after surgery.

Enrollment: 160
Study Start Date: July 2008
Study Completion Date: June 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
atrial pacing
amiodarone plus atrial pacing


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
adult patients undergoing open heart surgery

Inclusion Criteria:

  • age > or = to 18 years
  • sinus rhythm
  • undergoing either coronary artery bypass graft surgery (CABG), valvular heart surgery or a combined procedure

Exclusion Criteria:

  • received a class-I or class-III antiarrhythmic agent in the past six months
  • had second or third degree heart block
  • had a resting heart rate of less than 50 beats per minute
  • had a systolic blood pressure less than 100 mmHg
  • had severe asthma or severe chronic obstructive pulmonary disease
  • had uncontrolled heart failure
  • had a serum aspartate aminotransferase or alanine aminotransferase concentration greater than four times the upper limit of normal
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01742039

United States, District of Columbia
George Washington University Hospital
Washington DC, District of Columbia, United States, 20037
George Washington University
Washington, District of Columbia, United States, 20037
Sponsors and Collaborators
George Washington University
  More Information

Responsible Party: George Washington University Identifier: NCT01742039     History of Changes
Other Study ID Numbers: AF01
Study First Received: November 14, 2012
Last Updated: December 3, 2012

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Anti-Arrhythmia Agents
Vasodilator Agents
Potassium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Sodium Channel Blockers
Cytochrome P-450 CYP1A2 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Cytochrome P-450 CYP2C9 Inhibitors
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 CYP3A Inhibitors processed this record on May 25, 2017